Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 2
2005 3
2006 3
2008 1
2014 1
2020 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, Pendem S, Newstrom D, Brockett R, Mikaelian I, Kusam S, Ramirez R, Lopez D, Li L, Fuchs BC, Breckenridge DG. Bates J, et al. Among authors: hollenback d. J Hepatol. 2020 Oct;73(4):896-905. doi: 10.1016/j.jhep.2020.04.037. Epub 2020 May 4. J Hepatol. 2020. PMID: 32376414 Free article.
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Vijayakumar A, Okesli-Armlovich A, Wang T, Olson I, Seung M, Kusam S, Hollenback D, Mahadevan S, Marchand B, Toteva M, Breckenridge DG, Trevaskis JL, Bates J. Vijayakumar A, et al. Among authors: hollenback d. Hepatol Commun. 2022 Sep;6(9):2298-2309. doi: 10.1002/hep4.2011. Epub 2022 Jun 23. Hepatol Commun. 2022. PMID: 35735253 Free PMC article.
Energy balance in congenital generalized lipodystrophy type I.
Taleban S, Carew HT, Dichek HL, Deeb SS, Hollenback D, Weigle DS, Cummings DE, Brunzell JD. Taleban S, et al. Among authors: hollenback d. Metabolism. 2008 Aug;57(8):1155-61. doi: 10.1016/j.metabol.2008.04.008. Metabolism. 2008. PMID: 18640396 Free PMC article.
Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.
Hollenback D, Hambruch E, Fink G, Birkel M, Schulz A, Hornberger M, Liu K, Staiger KM, Krol HD, Deuschle U, Steeneck C, Kinzel O, Liles JT, Budas G, Watkins WJ, Kremoser C. Hollenback D, et al. J Pharmacol Exp Ther. 2024 Feb 26:JPET-AR-2023-001900. doi: 10.1124/jpet.123.001900. Online ahead of print. J Pharmacol Exp Ther. 2024. PMID: 38409114 Free article.
14 results